ARPO - Aerpio slips after Aadi Bioscience updated data for cancer agent nab-sirolimus

Aerpio Pharmaceuticals (ARPO) is trading ~6.8% lower after announcing that privately-held Aadi Bioscience disclosed the publication of an abstract which will be part of a poster session at the upcoming American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.This week, Aerpio announced a merger agreement with Aadi. The transaction expected to close in Q3 2021 will see Aerpio changing its name to “Aadi Bioscience, Inc.”“The combined public company will focus on advancing Aadi’s lead product candidate, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009),” the two companies said.The abstract is about a presentation scheduled at ASCO 2021 on June 04. It relates to antitumor activity in a group of patients with TSC1 or TSC2 alterations and neoplasms other than advanced malignant PEComa, a family of rare tumors affecting soft tissues of the stomach, intestines etc. The patients had received single-agent nab-sirolimus in an in an expanded access program (NCT03817515).At the time

For further details see:

Aerpio slips after Aadi Bioscience updated data for cancer agent nab-sirolimus